We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ABVX market cap is 385.75M. The company's latest EPS is EUR -2.3477 and P/E is -2.61.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 23k | 6.75M | 11.96M | 4.58M | 4.62M |
| Operating Income | -33.3M | -33.17M | -41.4M | -64.84M | -127.38M |
| Net Income | -30.63M | -37.63M | -42.45M | -60.74M | -147.74M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 51.73M | 69.71M | 109.23M | 75.54M | 327.06M |
| Total Liabilities | 39.95M | 67.98M | 83.3M | 68.36M | 131.05M |
| Total Equity | 11.78M | 1.73M | 25.93M | 7.19M | 196.01M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -27.47M | -27.99M | -45.05M | -53.94M | -97.13M |
| Investing | -370k | -513k | -6.23M | -12.03M | -8.1M |
| Financing | 24.61M | 48.03M | 82.68M | 32.21M | 335.29M |
| Market Cap | 385.75M |
| Price to Earnings Ratio | -2.61 |
| Price to Sales Ratio | 83.51 |
| Price to Cash Ratio | 1.53 |
| Price to Book Ratio | 1.97 |
| Dividend Yield | - |
| Shares Outstanding | 62.93M |
| Average Volume (1 week) | 39.42k |
| Average Volume (1 Month) | 91.94k |
| 52 Week Change | -52.70% |
| 52 Week High | 15.42 |
| 52 Week Low | 5.62 |
| Spread (Intraday) | 0.2 (3.23%) |
| Company Name | Abivax |
| Address |
7-11 boulevard haussmann paris, paris 75009 |
| Website | https://www.abivax.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
